Stryker Corp (SYK)
328.45
+1.82
(+0.56%)
USD |
NYSE |
May 03, 16:00
334.08
+5.63
(+1.71%)
Pre-Market: 09:11
Stryker Enterprise Value: 135.58B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 135.58B |
| May 02, 2024 | 134.89B |
| May 01, 2024 | 135.46B |
| April 30, 2024 | 138.65B |
| April 29, 2024 | 139.55B |
| April 26, 2024 | 138.31B |
| April 25, 2024 | 138.90B |
| April 24, 2024 | 138.78B |
| April 23, 2024 | 138.04B |
| April 22, 2024 | 135.29B |
| April 19, 2024 | 134.43B |
| April 18, 2024 | 135.20B |
| April 17, 2024 | 138.47B |
| April 16, 2024 | 139.09B |
| April 15, 2024 | 139.65B |
| April 12, 2024 | 140.76B |
| April 11, 2024 | 142.38B |
| April 10, 2024 | 142.77B |
| April 09, 2024 | 144.14B |
| April 08, 2024 | 143.70B |
| April 05, 2024 | 144.18B |
| April 04, 2024 | 142.79B |
| April 03, 2024 | 144.17B |
| April 02, 2024 | 143.55B |
| April 01, 2024 | 145.57B |
| Date | Value |
|---|---|
| March 31, 2024 | 146.79B |
| March 28, 2024 | 146.10B |
| March 27, 2024 | 146.42B |
| March 26, 2024 | 143.25B |
| March 25, 2024 | 143.50B |
| March 22, 2024 | 144.10B |
| March 21, 2024 | 144.44B |
| March 20, 2024 | 144.32B |
| March 19, 2024 | 145.73B |
| March 18, 2024 | 144.66B |
| March 15, 2024 | 143.95B |
| March 14, 2024 | 145.25B |
| March 13, 2024 | 145.73B |
| March 12, 2024 | 146.30B |
| March 11, 2024 | 145.23B |
| March 08, 2024 | 146.03B |
| March 07, 2024 | 145.93B |
| March 06, 2024 | 144.94B |
| March 05, 2024 | 143.94B |
| March 04, 2024 | 145.26B |
| March 01, 2024 | 144.26B |
| February 29, 2024 | 142.68B |
| February 28, 2024 | 143.72B |
| February 27, 2024 | 143.87B |
| February 26, 2024 | 143.97B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
54.08B
Minimum
Mar 23 2020
146.79B
Maximum
Mar 31 2024
101.62B
Average
102.92B
Median
Enterprise Value Benchmarks
| Boston Scientific Corp | 115.63B |
| Haemonetics Corp | 5.471B |
| Abbott Laboratories | 191.38B |
| Zimmer Biomet Holdings Inc | 30.60B |
| ResMed Inc | 32.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 788.00M |
| Revenue (Quarterly) | 5.243B |
| Total Expenses (Quarterly) | 4.271B |
| EPS Diluted (Quarterly) | 2.05 |
| Gross Profit Margin (Quarterly) | 63.57% |
| Profit Margin (Quarterly) | 15.03% |
| Earnings Yield | 2.67% |
| Operating Earnings Yield | 3.28% |
| Normalized Earnings Yield | 2.680 |